Martin Brenner

Martin Brenner

Chief Executive Officer at IBIO, INC.

Net worth: 38 928 $ as of 31/08/2026

56 year
Health Technology
Consumer Services

Profile

Dr. Martin B. Brenner is a Director, Chief Executive & Scientific Officer at iBio, Inc. He is on the Board of Directors at iBio, Inc. Dr. Brenner was previously employed as a Chief Scientific Officer & Senior Vice President by The Pelican, Inc., a Chief Scientific Officer by Recursion Pharmaceuticals, Inc., a VP & Head-Research & Early Development by ASOTHERA PHARMAECUTICALS INC, an Executive Director-Diabetes & NASH by Merck Research Laboratories Massachusetts LLC, a Senior Director & Head-BioScience by AstraZeneca PLC, and a Head-Insulin Resistance Group by Pfizer Inc. He received his doctorate degree from Ludwig-Maximilians-Universität München and a doctorate degree from The University of Veterinary Medicine Hanover.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
01/09/2026 30,652 ( 0.09% ) 38 928 $ 31/08/2026

Martin Brenner active positions

CompaniesPositionStart
IBIO, INC. Chief Executive Officer 20/01/2023

Former positions of Martin Brenner

CompaniesPositionEnd
PFENEX INC. Chief Tech/Sci/R&D Officer 01/10/2020
RECURSION PHARMACEUTICALS, INC. Chief Tech/Sci/R&D Officer 01/01/2018
STOKE THERAPEUTICS, INC. Corporate Officer/Principal 01/01/2017
Director/Board Member 01/01/2016
ASTRAZENECA PLC Corporate Officer/Principal 01/01/2013
See the detail of Martin Brenner's experience

Training of Martin Brenner

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

57

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies9

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

  1. Stock Market
  2. Insiders
  3. Martin Brenner